Do the patients with peripheral atherosclerosis need to a medical therapy before the revascularization?

Abstract

In the review article are provided the approaches to the therapy for improvement of prognosis in patients with peripheral and multifocal atherosclerosis which are available now; some limitations and a real situation are designated for the antithrombotic therapy in this category of patients. According to the clinical trial COMPASS the prospects of wide use of a combination of acetylsalicylic acid and a rivaroxsaban of 2.5 mg 2 times a day in the patients with chronic coronary heart disease and/or symptom peripheral atherosclerosis are designated.

Keywords

• peripheral atherosclerosis
• chronic coronary heart disease
• multifocal atherosclerosis
• prognosis
• antithrombotic therapy
• rivaroxaban